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Macrophages are terminally differentiated cells of the mononuclear phagocyte system that also
encompasses dendritic cells, circulating blood monocytes, and committed myeloid progenitor
cells in the bone marrow. Both macrophages and their monocytic precursors can change their
functional state in response to microenvironmental cues exhibiting a marked heterogeneity.
However, there are still uncertainties regarding distinct expression patterns of surface markers that
clearly deﬁne macrophage subsets, particularly in the case of human macrophages. In addition to
their tissue distribution, macrophages can be functionally polarized into M1 (proinﬂammatory) and
M2 (alternatively activated) as well as regulatory cells in response to both exogenous infections
and solid tumors as well as by systems biology approaches.
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1. MACROPHAGE POLARIZATION: DOGMA OR REALITY?
Proinﬂammatory, “classical Activation” of macrophages, which was delineated in early studies from the
1960s [1, 2], depends on the secreted molecules of activated T helper 1 (Th1) CD4+ lymphocytes or
natural killer (NK) cells, and in particular of interferon-γ (IFN-γ), and of other proinﬂammatory agents
such as tumor necrosis factor-α (TNF-α) and bacterial lipopolysaccharide (LPS). Classical activation
results in a population of macrophages with enhanced microbicidal capacity and increased secretion of
proinﬂammatory cytokines to further strengthen the cell-mediated adaptive immunity [3, 4]. In contrast,
interleukin-4 (IL-4) and IL-13, signature cytokines of the CD4+ Th2 response, namely, are the major
inducers of the “alternative activation” of macrophages that play an important role not only in the immune
response to parasites, but also in allergy, wound healing, and tissue remodeling [5, 6].
Indeed, “classically” and “alternatively” activated macrophages have been designated as “M1” and
“M2” macrophages, respectively, by analogy to the Th1/Th2 division of labor of CD4 helper T cells [7].
M2-polarized macrophages are further subdivided into M2a (elicited by IL-4 or IL-13), M2b (following
stimulation by immune complexes in the presence of a Toll-like receptor ligand), and M2c (when exposed
to anti-inﬂammatory stimuli such as glucocorticoid hormones, IL-10, or Transforming Growth Factor-β,
TGF-β)[ 8]. Although this classiﬁcation of macrophages provides a useful working scheme, it unlikely
fully represents the complexity of the transitional states of macrophage activation, which is often ﬁne tuned
in response to different microenvironments.
Am o r eﬂexible classiﬁcation has been suggested recently by mouse studies in which macrophages
are considered as part of a continuum having a range of overlapping functions and in which classically
activated, wound-healing, and regulatory macrophages occupy different points of the spectrum [9].
However, also this classiﬁcation does not take into account the role of macrophages during development
encompassing embryonic [10] and wound-healing [9] macrophages as well as irreversibly differentiated
osteoclasts [11]. The differentiation of these different macrophages is profoundly inﬂuenced by the
microenvironment, although there is considerable plasticity between distinct cell types. This concept recalls
Metchnikoff’s original classiﬁcation that considered macrophages as part of a continuum, keeping the self
whole in development and adulthood (physiological inﬂammation) and differentiating it from nonself and
the environment (pathological inﬂammation).
2. MACROPHAGE PLASTICITY: AN OBSTACLE TO STUDY
MACROPHAGE POLARIZATION?
Unlike lymphocytes where phenotypic changes are largely “ﬁxed” by chromatin modiﬁcations after
exposure to polarizing cytokines, macrophages have a plastic gene expression proﬁle that is inﬂuenced by
the type, concentration, and longevity of exposure to the stimulating agents, as documented extensively
[9, 12–14]. For example, M2 macrophages can be readily induced to express M1-associated genes by
exposure to TLR ligands or IFN-γ [15–17]. Indeed, gene expression plasticity was the rule rather than the
exception when experimental polarization was performed [15–17]. In this regard, gene expression plasticity
represents an adaptive response to different microenvironmental stimuli, in which macrophages migrate in
response to chemotactic signals or chemokines, phagocytose dead cells and debris, and functionally interact
with different T cell subsets.
Macrophages are renown for their apparent phenotypic heterogeneity and for the diverse activities
in which they engage [18, 19]. Many of these activities appear to be opposing in nature: pro- versus anti-
inﬂammatory effects, immunogenic versus tolerogenic activities, and tissuedestruction versus tissue-repair
[6, 18, 19]. Indeed, signiﬁcant differences between genes expressed early (up to 6h) versus late (12–24h or
later) after LPS stimulation have been reported [20]. Thus, the functional pattern expressed by macrophages
changes with time as the response progresses. It should also be noted that macrophages frequently respond
to the early cytokines that they secrete in an autocrine/paracrine fashion. Macrophages treated overnight
with IL-4 prior to stimulation with LPS display enhanced production of TNF-α and IL-12, in stark contrast
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to the reduced production of these cytokines observed upon stimulation with LPS in the presence of IL-4
[21].
There is a high number of factors contributing to diversity of macrophage function, including the
synergistic or antagonistic effects of different cytokines and related signals on their differential expression,
chemokines, hormones (including adrenergic and cholinergic agonists), TLR ligands, and other endogenous
ligands (e.g., histamine, integrin ligands, peroxisome proliferator-activated receptor ligands, apoptotic
cells); this plethora of signals underlines the fact that macrophages can display a large number of distinct,
functional patterns that have not yet been completely deﬁned. Furthermore, identical macrophages placed
in different microenvironments display different functions in response to a common stimulus. Stimulation
of macrophages with functionally opposite cytokines, such as IFN-γ and IL-4, initiates signal cascades
that results in differential modulation (enhancement or inhibition) of different genes at the transcriptional
or posttranscriptional level (e.g., stabilization or destabilization of mRNA). Unless the signal cascade
triggered an apoptotic cascade, macrophages will eventually revert to their original, functional status after
the cytokine signaling ceases.
In vivo or in vitro treatment of macrophages with cytokines alters their functional response pattern
to LPS. However, if the cytokines are washed away after incubation and macrophages are then maintained
in the absence of cytokines for 1-2 days before LPS stimulation, the functional response pattern is usually
identical to that of macrophages that had not been prestimulated with the cytokine. A similar reversion to
basal macrophage phenotype is observed when IL-4 and granulocyte macrophage-colony-stimulating factor
(GM-CSF) are removed from human monocyte-derived, immature dendritic cells (iDCs) and the cells are
resuspended in a neutral environment [22].
Therefore,mostTh1andTh2cytokinesdonot seemtoinduceastabledifferentiation ofmacrophages
into distinct subsets, but they rather promote a transient functional pattern of responses that return to basal
levels in a few (3–7) days.
3. MARKERS OF MACROPHAGE POLARIZATION: STILL AN OPEN CHASE
One of the most debated issues in the context of human macrophage polarization is the identiﬁcation
of unique or restricted markers to be used for research and clinical purposes. Innovative approaches,
including intravital imaging and other in vivo techniques, will be of great help in the identiﬁcation of “real”
subsets of macrophages in addition to more static antigens expressed on their cellular surface following
cell polarization. An example of this broader approach is summarized by the identiﬁcation of at least 6
different subsetsof mousetumor-associated macrophages(TAMs) basedon their distinct functional features
(Table 1), as reviewed in [24]. According to this view, every macrophage subset not only expresses different
cytokinesandcytokine receptorsbutalso playsa complete distinct role in tumor pathogenesisandevolution,
from tumor initiation to tumor metastasis.
4. CONTRIBUTION OF MACROPHAGE POLARIZATION TO
INNATE IMMUNE RESPONSES
Mononuclear phagocytes play a pivotal role in the establishment of antiviral immune responses. Unlike
mDCs that capture antigens in mucosal tissues and then migrate to distal lymph nodes to activate speciﬁc
T-cell responses, tissue macrophages are residential cells. Macrophages constitute up to 20% of all
mononuclear cells present in mucosal tissues and play an important role in activating localized responses
[43].
While M1 and M2 macrophages facilitate the development of Th1 and Th2 responses, respectively
[3, 9, 19, 44], their role in the modulation of natural killer (NK) and T regulatory (Treg) immunosuppressive
remains undeﬁned. NK cells are a critical component of innate immune response. They promote antiviral
immunity by killing infected cells, via production of inﬂammatory cytokines and by interactions with T
cells with DC, a process that shapes the magnitude and quality of adaptive immune responses [45]. A recent
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TABLE 1: Subpopulations of macrophages in different pathologies.
Disease Markers References
Cancer
Invasive macrophages WNT+,E G F + [25–28]
Activated macrophages IL-12+,M H CI I HI,T N F - α+, CD80/86+ [29, 30]
Immunosuppressive macrophages Arginase+, MARCO+,I L - 1 0 +, CCL-22+ [31, 32]
Angiogenic macrophages
VEGFR1+,V E G F +, CXCR4+,T i e 2 +,
EST2+ [33–36]
Metastasis-associated macrophages VEGFR1+, CXCR4−, CCR2+,T i e 2 − [24, 37–39]
FoxP3+ macrophages (regulatory
macrophages)
PGE2,A r g - 2 ,I L - 1 α, CXCL4, CCL7,
CCL9, CXCL12, CXCL13, PDGF, and
VEGF
[40]
HIV
HIV-transmitting macrophages
DC-SIGN+, CD163, CD206, High
Phagocytosis
(Cassol et al., submitted)
HIV-resistant macrophages APOBEC3A+, Low phagocytosis (Cassetta et al., submitted)
Other
Perivascular macrophages Phagocytosis [41, 42]
study by Romo et al. showed that both M1 and M2 cells were able to trigger NK cell degranulation but
that only M1 cells infected with the human cytomegalovirus efﬁciently promoted NK-cell-mediated IFN-γ
production [46]. Further studies will be required to understand if similar events occur in the case of other
viral infections.
If Treg cells, on the one hand, are potent suppressors of the adaptive immune response, on the other
hand it is less know how they affect the innate immune system. Tiemessen et al. showed that Tregs can
steer monocyte differentiation towards alternative activation resulting in increased expression of CD163
and CD206, increased production of CCL18, and enhanced phagocytic capacity [47]. Interestingly, Savage
et al. demonstrated that M2, but not M1, macrophages induced differentiation of Treg cells with a strong
suppressive phenotype [48]. Their mechanism of action required cell-cell contact and involved membrane-
bound TGF-β1 expression [48]. Thus, macrophage polarization can indeed modulate multiple aspects of
both the adaptive and innate immune responses.
5. REGULATORY MACROPHAGES (RMs)
As mentioned, diversity is a key feature of macrophage activation. In addition to M1 and M2 macrophages,
RMs have recently emerged as an important population of cells that play a pivotal role in limiting
inﬂammation during innate and adaptive immune responses [9, 44]. Similar to M2 macrophages, RMs
produce high levels of IL-10; however, unlike M2 cells, they do not contribute to the production of
extracellular matrix and express high levels of the costimulatory molecules CD80/B7-1 and CD86/B7-2
[9, 49]. Studies in mice have demonstrated a crucial role for both IL-4/IL-13 and IFN-γ signaling pathways
in the induction of RM [50, 51]. Furthermore, they have shown that regulatory cells concurrently express
nitric oxide synthase and arginase (Arg) suggesting that they have a distinct activation phenotype [3]. Given
the potent T-cell suppressive function of RM, it will be important to develop reliable biomarkers for their
identiﬁcation.
Interestingly, a recent study has identiﬁed a subpopulation of Foxp3+ macrophages in the mouse
[40]. These cells, which are distributed throughout the major lymphoid organs, inhibit T-cell proliferation.
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Manrique et al. reported that F4/80+Foxp3− cells could be converted into FoxP3+ cells by stimulation
with TGF-β, Vascular Endothelial Growth Factor (VEGF), or TLR ligands [40]. According to their
study, Foxp3+ macrophages inhibit immune responses via both the secretion of soluble factors (such as
prostaglandin E2,P G E 2, arginase-2, Arg-2, IL-1α, CXCL4, CCL7, CCL9, CXCL12, CXCL13, platelet
derived growth factor, and VEGF) and induction of cell death by increased expression of TRAIL, CD200r,
LAG3, B7-H1, B7H-4, and PD1 [40]. Foxp3+ macrophages also promote the development of Treg cells
[40]. Based on cytokine and transcriptional proﬁles, the authors deﬁne these cells as “Foxp3 RM”; it is
currently unclear if a similar population exists in humans.
Although cell activation is critical for the induction of an effective immune response to pathogens or
tumors, inappropriate and sustained activation/polarization of macrophages leads to tissue damage, immune
dysfunction, and disease. As with exacerbated M1 and M2 responses, dysfunctional regulatory responses
contribute to tumor progression and growth (as discussed below) and can predispose the host to infection.
Several pathogens including Staphylococcus aureus [52], Leishmania [53], and African Trypanosomas [54]
exploit regulatory responses to facilitate immune escape and enhance their own survival in the host. For
example, Leishmania binds and triggers FcγR signaling during entry, resulting in the development of RM
which are permissive to its intracellular growth [53]. Given their capacity to suppress adaptive immune
responses, it will be important to understand more clearly how RMs contribute to dysfunctional immune
responses in chronic viral infections such as HIV.
6. MACROPHAGE DIVERSITY IN SYSTEMS BIOLOGY
Systems biology approaches have provided important insights into the heterogeneity of mononuclear
phagocyte populations, the plasticity of macrophage activation, and the molecular pathways associated
with polarization. Transcriptome proﬁling has been commonly used to examine networks of molecules
and transcription factors linked to activation. Using this approach, Martinez et al. obtained a comprehensive
global view of human macrophage polarization [19]. Expanding on previous studies of M1 and M2 markers,
they found that while M1 polarization was associated with dramatic changes in the transcriptome, M2
polarization resulted in minimal alterations in gene expression. The modulation of genes involved in cellular
metabolic activities was a prominent feature of polarization. These genes included a set of apolipoproteins
(APOL1, APOL2, APOL3, and APOL6) that play a central role in cholesterol transport [19]. More recent
transcriptome studies have focused on understanding the spectrum of polarization phenotypes associated
with disease. Pena et al. found that the range of changes observed during LPS tolerance, including the
upregulation of genes important in wound repair (MMP-9, MMP-7, VEGF, FGF-2, and f-MLPR ligand-1),
were similar to changes observed during M2 polarization [55]. This led the authors to propose that LPS
tolerance represents a distinct state of M2 polarization.
Epigenetic studies have begun to unravel how polarized macrophages acquire and maintain their
activation phenotype. M2 genes in mice, including Chi3l3, Retnla, and Arg-1, were shown to be
epigenetically regulated as a result of signal transducer and activator of transcription 6-(STAT6-) dependent
induction of the H3K27 demethylase Jmjd3 [56]. Furthermore, Satoh et al. found that Jmjd3 was a gene
essential for M2, but not M1, macrophage polarization in response to helminthic infections [57]. They also
identiﬁed Irf4 as a Jmjd3 target gene, a key transcription factor that controls M2 polarization. More recently,
Zhang et al. observed that genes with a potential for increased/decreased expression after macrophage
polarization (i.e., IFN-γ,I F N - α, and IL-4) were generally enriched for cytokine-induced H4 acetylation
(H4ac), a marker of increased transcriptional competence [58]. Furthermore, monocyte (and potentially
macrophage) polarization was heterogenous with respect to durability. This systems approach identiﬁed
mitogen-activated protein (MAP) kinases as central to the polarization process consistent recent studies
highlighting the role of MAP kinases in histone modiﬁcation [58].
Thus, systems biology will keep providing a constantly updated global view of the networks
regulating or involved in macrophage polarization, allowing us to evaluate key issues related to macrophage
heterogeneity and plasticity.
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7. MACROPHAGE POLARIZATION IN CANCER BIOLOGY: A MATTER OF
GOOD OR BAD EDUCATION
All solid tumors recruit monocytes and local macrophages into their microenvironment making them TAM;
it is being increasingly clear that TAMs play several, sometimes opposite, roles during tumor development.
Originally it was believed that these cells were attempting to reject the immunologically non-self entity
made of transformed cells (that frequently lose or modify their MHC proﬁle). Indeed, macrophages can
effectively kill tumor cells in vitro [59]. However, clinical and experimental evidence indicates that, in most
cases, TAMs promote rather than counteract tumor progression, including their metastatic phase [25, 60,
61]. For example, the density of TAM in human tumors correlates with poor prognosis in >80% of the cases
[62].
These observations suggest that the tumor environment causes recruited macrophages to carry out
trophic functions for cancer cells by adopting an M2-related proﬁle. In fact, macrophages that differentiate
in the presence of growth factors such as M-CSF/Colony-Stimulating Factor-1 (CSF-1) [63] or in response
to stimuli of the nuclear factor-κB( N F - κB) activation pathway [64, 65] are nonimmunogenic and exert
trophic effects on the tumor growth. In this regard, it is important to underscore that TAMs found in
progressing tumors are different from macrophages mediating chronic inﬂammatory responses to pathogens
or irritants that may be involved in cancer initiation by creating a mutagenic and cell-growth-promoting
environment [66, 67]. Indeed, TAM isolated from progressing tumors are functionally similar to those found
in developing tissues [68], therefore supporting the hypothesis that tumors can “diseducate” macrophages
to facilitate tumor progression and invasion (Table 1).
In conclusion, tumors can affect macrophages playing with their impressive plastic nature in order
to modify the microenvironment and consequently alter the function and the strength of the cellular and
innate immune response. These studies together provide useful models to investigate how cancer cells (and
viruses, as discussed later on) crosstalk with macrophages; the potential application of this information will
be the identiﬁcation of soluble factors or inhibitors that will “reeducate” macrophages against pathogens
and neoplastic lesions.
8. MACROPHAGE POLARIZATION IN HIV INFECTION AND
OTHER VIRAL DISEASES
The role of macrophage polarization in viral infections is far from being well deﬁned. In this regard, a good
example of macrophage education by a pathogen is represented by HIV-1. While in advanced patients
the most prominent dysfunction is defective migratory responses of circulating monocytes to classical
chemoattractants [69, 70], later linked to a downregulation of chemotactic receptors for C5a and for the
bacterial tripeptide f-MLP [71, 72], monocytes as well as lung alveolar macrophages isolated from HIV+
individuals have also shown reduced phagocytic activity [73, 74], decreased phagosome-lysosome fusion,
and decreased intracellular killing of opportunistic pathogens [73, 75]. These functional defects, in turn,
result in the inefﬁcient control of opportunistic pathogens and further enhancement of cell activation and
disease pathogenesis.
Chronic HIV-1-associated immune activation also leads to altered secretion of pro- and anti-
inﬂammatory cytokines and chemokines and, ultimately, to dysregulation of the host immune system
and the killing of bystander CD4+ T cells. In addition, HIV-infected macrophages have been implicated
in the elimination of effector CD8+ T cells through interactions between TNF bound to the surface of
macrophages and TNFRII expressed on CD8+ T cells [76]. Of interest, Brown et al. found that in vitro
incubation with HIV-1 failed to induce classical macrophage activation via TLR, although the virus primed
macrophagestobecomehyperresponsivetoTLRligands,aphenotypedesignatedbytheauthorsas“M1HIV”
[77].
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FIGURE 1: A model of M1-MDM as “HIV-1-resistant macrophages.” (1) Downmodulation of CD4 and
production of CCR5-binding chemokines that compete with gp120 Env for the ligation to the main viral
entry coreceptor [23]. (2) Inhibition of viral DNA synthesis and proviral integration [23], (L. Cassetta et
al. submitted). (3) Inhibition of proviral transcription (L. Cassetta et al., submitted). (4) Inhibition of HIV-1
protein synthesis [23], (L. Cassetta et al., submitted). (5) Inhibition of new particle assembly and release
(hypothetical).
We have reported that MDM polarized in vitro towards M1 or M2a cells strongly inhibited HIV-
1 replication and production, although affecting different steps of the virus life cycle [23]. Based on
our results, we can envisage M2a-polarized macrophages as “HIV-1-transmitting macrophages” in that
characterized by the selective expression of the molecule known as dendritic cell-speciﬁc intercellular
adhesion molecule-3-grabbing nonintegrin (DC-SIGN+, CD209) (that is otherwise downregulated in M1-
MDM, therefore representing a potentially useful marker for discriminating M1 and M2 macrophages).
Indeed, although M2a show lower levels of virus replication than control MDM, they can transfer efﬁciently
HIV-1 to CD4+ T cells via DC-SIGN (E. Cassol et al., submitted). In contrast, M1-MDM can be deﬁned
as “HIV-1-resistant macrophages” in that they show very low levels of virus replication as a result of both
entry- and post-entry-dependent hurdles to the virus in order to complete its replicative cycle. In addition to
being negative for DC-SIGN display at the cell surface, they are positive for the intracellular expression of
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A (APOBEC3A), a molecule that has
been associated to an antiviral effect in monocytes [78] and, more recently, in MDM [79, 80] (L. Cassetta
et al., submitted). The features typical of M1-MDM that are related to the restriction of HIV-1 replication
are summarized in Figure 1.
9. CONCLUSIONS
The concept that, in addition to the adaptive response, also the complex network globally deﬁned as
“innate immuniaty” can be specialized and “pathogen speciﬁc,” to some extent, led to the hypothesis
that macrophage activation could follow different programs with the goal of combat distinct pathological
situations or maintain a physiological homeostatic control of the local ﬂora, as in the case of the
gastrointestinal tract mucosa. Investigation of cancer, viral infections, and other pathological conditions
will also inform on the plasticity and heterogeneity of macrophages and hopefully lead to better strategies
to control and prevent the occurrence of these diseases.
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